The market experienced a rollercoaster of a week, with stocks bouncing back on Monday and seeing modest losses on Tuesday. However, the tech selloff that haunted the previous week swiftly resumed following disappointing earnings from Alphabet (GOOGL) and Tesla (TSLA). Wednesday witnessed the S&P 500 Index (SPX) and Nasdaq Composite Index (IXIC) suffer their worst ...
RapidEye After analyzing the Phase 3 data of the drug Multikine in the treatment of head and neck cancer, CEL-SCI’s stock on NYSE surged by 40% in morning trading on Friday. The company revealed that Multikine managed to reduce the five-year risk of death by 50% as per the results of the study. “The bias ...
Artificial intelligence (AI) stands as a phoenix, reborn to revolutionize industries far and wide. From the realms of self-driving vehicles to the nooks of drug discovery and content creation, AI unfurls its wings over the canvas of business, rewriting the very essence of innovation. For the vigilant investors seeking the beacon of opportunity amidst the ...
Microsoft‘s MSFT fourth-quarter fiscal 2024 results, scheduled for reporting on Jul 30, are anticipated to be amplified by the unwavering ascent of its cloud arm, Azure. Azure’s Continued Growth Propelling Microsoft’s Q4 Revenues Microsoft is currently observing an upsurge in demand for various cloud services, driven by the escalating shift of workloads to the cloud. ...
Quest Diagnostics’ DGX subsidiary, Haystack Oncology, and Lisata Therapeutics, Inc. LSTA recently announced a research collaboration for using the Haystack MRD (minimal residual disease) technology. Under the partnership, Lisata will deploy the highly sensitive technology to detect the circulating tumor DNA (ctDNA) in a clinical study evaluating certepetide plus chemotherapy as an investigational treatment for ...
Seeking Opportunities Amidst Oversold Market Trends In the ever-evolving landscape of the stock market, the consumer discretionary sector beckons with tantalizing prospects for savvy investors. The recent downtrend in certain stocks has created a unique window of opportunity to delve into undervalued companies, potentially reaping substantial rewards in the process. Unveiling the Oversold Players An ...
Check Point Software Technologies CHKP reported excellent second-quarter 2024 results, exceeding both the Zacks Consensus Estimate and showing improvement year over year. The IT security solutions provider reported non-GAAP earnings of $2.17 per share, outshining the Zacks Consensus Estimate of $2.16, with an 8% increase from the year-ago quarter’s earnings of $2 per share. Check ...
Unlocking Insights into Norfolk Southern’s Options: A Closer Look Deciphering the Recent Norfolk Southern Options Activity Big-spending investors are making bold moves, striking a bullish chord on Norfolk Southern (NSC). For retail traders catching wind of this, it’s a noteworthy development. The signals emerged vividly on our radar as we parsed through the publicly available ...
Analyzing Noteworthy Option Trends Today’s options trading activity within the components of the Russell 3000 index has sparked a keen interest, particularly involving Goosehead Insurance Inc (GSHD), where a substantial volume of 1,323 contracts has changed hands. This volume is equivalent to about 132,300 underlying shares, representing an impressive 47.8% of GSHD’s average daily trading ...
Nvidia (NVDA) Nvidia (NASDAQ:NVDA) has been the star of the Nasdaq 100 in 2024, boasting a remarkable 147% increase in its stock value year-to-date. The demand for its artificial intelligence chips has been a primary driver of this phenomenal growth. Nvidia’s relentless innovation and strategic software development have positioned it as the premier AI chipmaker ...
